The Attitudes and Experiences of Advanced Practice Nurse Practitioners on Point of Care Ultrasonography Save

Date Added
August 12th, 2016
PRO Number
Pro00056005
Researcher
Calla Sanders
Keywords
Education, Men's Health, Non-interventional, Women's Health
Summary

Our belief is that point-of-care ultrasound has not transcended into the nurse practitioner?s clinical practice in the form of formal or informal training. This survey aims to determine the accessibility to and utility of point-of-care ultrasound amongst nurse practitioners for patient evaluation as well as gauge their interest in formalized training.

Institution
Palmetto
Recruitment Contact
Alisha Henderson
545-5453
alisha.henderson@uscmed.sc.edu

A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma Save

Date Added
August 9th, 2016
PRO Number
Pro00055991
Researcher
Harry Drabkin
Keywords
Cancer, Cancer/Genitourinary, Drug Studies, Kidney, Men's Health, Women's Health
Summary

The purpose of this study is to evaluate the progression free survival (PFS) , based on investigator radiologic review, of AGS-16C3F compared to axitinib in adult subjects with metastatic renal cell carcinoma. The time frame for PFS is 24 months.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

An open-label, multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligible for standard induction and consolidation chemotherapy Save

Date Added
August 9th, 2016
PRO Number
Pro00057572
Researcher
Robert Stuart
Keywords
Cancer, Drug Studies, Men's Health, Women's Health
Summary

This study is for patients that have been diagnosed with acute myeloid leukemia with mutations in the Fms-like tyrosine kinase receptor (FLT3). The investigational drug in this study is midostaurin. The purpose of this study is to provide access to midostaurin and gather additional safety data on the combination of midostaurin and standard chemotherapy in subjects 18 years of age, or older, with newly diagnosed AML that have a FLT3 mutation (ITD or TKD). Participants can expect to be in this study for about 1 year.

Institution
MUSC
Recruitment Contact
HCC Clincal Trials Ofiice
843-792-9321
hcc-clinical-trials@musc.edu

Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial: A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) with or without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer Save

Date Added
June 21st, 2016
PRO Number
Pro00053734
Researcher
David Marshall
Keywords
Cancer, Cancer/Gastrointestinal, Men's Health, Pancreas, Women's Health
Summary

The goal of this study is to determine the safety and efficacy of a chemotherapy regimen known as Modified FOLFIRINOX (mFFX) alone or with the addition of Stereotactic Body Radiotherapy (SBRT). SBRT is a type of highly focused and precise x-ray treatment done in a total of 5 treatments. We hope to learn if this new treatment combination helps to control the disease and improve survival for patients with locally advanced pancreatic cancer.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma Save

Date Added
June 14th, 2016
PRO Number
Pro00054969
Researcher
Juan Varela
Keywords
Cancer, Drug Studies, Men's Health, Women's Health
Summary

This study is for patients that have been diagnosed with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The investigational drug in this study is MEDI4736, tremelimumab and AZD9150. The purpose of this study is designed to find out the best dose of experimental drugs called MEDI4736, tremelimumab and AZD9150. The research study will also investigate how safe MEDI4736 is when given alone or together with tremelimumab or AZD9150 in participants with DLBCL. Participants can expect to be in this study for up to 4 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Adapting Web-Based ASAP (Alcohol and Sexual Assault Prevention) for Veterans Save

Date Added
June 7th, 2016
PRO Number
Pro00053156
Researcher
Amanda Gilmore
Keywords
Alcohol, Healthy Volunteer Studies, Mental Health, Military, Substance Use, Women's Health
Summary

The goal of this study is to receive Veteran feedback on an intervention being developed for female Veterans to reduce their risk of alcohol misuse and sexual assault. We are recruiting 20 female Veterans who engage in alcohol misuse to receive feedback on the intervention content. Feedback will be integrated into the intervention prior to being used with female Veterans.

Institution
MUSC
Recruitment Contact
Amanda Gilmore
843-792-8348
gilmoram@musc.edu

A PHASE 1/2 STUDY OF VADASTUXIMAB TALIRINE (SGN-CD33A) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS) INTERMEDIATE-2 OR HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) Save

Date Added
May 24th, 2016
PRO Number
Pro00053610
Researcher
Robert Stuart
Keywords
Cancer, Drug Studies, Men's Health, Women's Health
Summary

This study is for patients that have been diagnosed with previously untreated Intermediate or High-risk myelodysplastic syndrome (MDS). The investigational drug in this study is vadastuximab talirine (SGN-CD33A). The purpose of this study is to evaluate escalating doses of vadastuximab talirine and compare the overall response rate between 2 study arms. Participants can expect to be in the study for up to approximately 39 months.

Institution
MUSC
Recruitment Contact
HCC-Clinical Trials Office
843-792-9321
hcc-clinical trials@musc.edu

Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma Save

Date Added
May 24th, 2016
PRO Number
Pro00054909
Researcher
Sara Giordano
Keywords
Cancer, Cancer/Breast, Drug Studies, Women's Health
Summary

The purpose of this study is to test study treatments that combine an investigational drug (ONT-380) with two approved drugs (capecitabine and trastuzumab) in subjects with advanced breast cancer to find out what effects, good or bad, it may have on you and your disease.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Phase 1/2a Study of Double-Immune Suppression Blockade by Combining a CSF1R Inhibitor (PLX3397) with an Anti-PD-1 Antibody (Pembrolizumab) to Treat Advanced Melanoma and Other Solid Tumors Save

Date Added
May 10th, 2016
PRO Number
Pro00054460
Researcher
Carolyn Britten
Keywords
Cancer, Men's Health, Women's Health
Summary

This research study is being conducted in order to test the safety of the investigational drug PLX3397 when given in combination with another drug called pembrolizumab. ?Investigational? means that PLX3397 is still being studied and that research doctors are trying to find out more about it. It also means that the U.S. Food and Drug Administration (FDA) has not approved PLX3397 for use in patients, including people with your type of cancer, outside of this study. Similarly, pembrolizumab is considered an investigational agent in this study.
PLX3397 works by blocking the activity of certain cells that are believed to limit an anti-cancer immune response by your body. Pembrolizumab specifically blocks another pathway that inhibits the capacity of your immune system to attack cancer cells. In combining PLX3397 and pembrolizumab, it is hoped that the capacity of your immune system to reject the cancer will be further enhanced than by the administration of either agent alone.

Approximately 508 subjects will take part in this study nation wide. 10 subjects will be enrolled at MUSC and will the under the care of Primary Investigator Dr. Carolyn Britten.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Pediatric Blood and Marrow Transplant Consortium (PBMTC) multi-center Phase II Pilot Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched T cell replete Bone Marrow with post-transplantation cyclophosphamide for Children and Young Adults with Hematologic Malignancies Save

Date Added
May 3rd, 2016
PRO Number
Pro00054276
Researcher
Michelle Hudspeth
Keywords
Cancer, Cancer/Other, Men's Health, Transplant, Women's Health
Summary

This study is for participants who have been diagnosed with cancers of the blood who do not have a related perfect tissue ?match? for BMT. This research is being done to find out if a bone marrow transplant (BMT) from a relative who is not a perfect tissue match is safe and effective in people with cancer. The primary goal of this study is to use chemotherapy and/or radiation therapy to completely get rid of a person?s existing bone marrow, give them new bone marrow from a relative who is not a perfect tissue match, and then give them two doses of additional chemotherapy shortly after receiving the new bone marrow. Participants can expect to be in this study for up to 2 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login